MUNICH (Reuters) - An investigational drug being studied as an antihypertensive, nebivolol (Mylan Laboratories), has been shown to significantly reduce rates of death or hospitalisation in heart failure patients over 70, regardless of gender or the type of heart failure.
Releasing the results at the annual congress of the European Society of Cardiology, researcher Andrew Coats of Sydney University told a news conference that the drug was very well tolerated by patients, who had an average age of 76.
The U.S. Food and Drug Administration in July accepted an application by Mylan to sell nebivolol in the United States.
Although the company is seeking approval for use of the drug to treat hypertension, Coats said he would be very surprised if the company did not use the data to seek approval for treating heart failure as well.
MeSH Headings:Congresses: Health Care Economics and Organizations: Organizations: Drugs, Investigational: Health CareCopyright © 2002 Reuters Limited. All rights reserved. Republication or redistribution of Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Reuters and the Reuters sphere logo are registered trademarks and trademarks of the Reuters group of companies around the world.
